• 1. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
• 2. Enantio- & chemo-selective preparation of enantiomerically enriched aliphatic nitro alcohols using Candida parapsilosis ATCC 7330
  Sowmyalakshmi Venkataraman RSC Adv., 2015,5, 73807-73813
• 3. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 4. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 5. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139

Introduction to (R)-4-Benzyl Albuterol and Its Applications in Modern Medicinal Chemistry

The compound with the CAS number 174607-68-2 is a specialized pharmaceutical intermediate known as (R)-4-Benzyl Albuterol. This compound has garnered significant attention in the field of medicinal chemistry due to its unique structural properties and potential therapeutic applications. Albuterol, a well-known β2-adrenergic receptor agonist, is primarily used for the treatment of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). The enantiomer (R)-4-Benzyl Albuterol represents a modified form of albuterol, where the stereochemistry has been specifically altered to enhance its pharmacological profile.

In recent years, there has been a growing interest in the development of enantiopure drugs due to their improved efficacy and reduced side effects compared to racemic mixtures. The (R)-isomer of albuterol, in particular, has shown promise in preclinical studies for its enhanced bronchodilatory effects. The introduction of a benzyl group at the 4-position of the albuterol molecule not only modifies its pharmacokinetic properties but also opens up new avenues for therapeutic intervention.

One of the key areas where (R)-4-Benzyl Albuterol has shown significant promise is in the treatment of severe asthma. Traditional β2-agonists like albuterol can lead to tachyphylaxis and other side effects when used over prolonged periods. However, the (R)-isomer appears to exhibit a more sustained effect with fewer adverse reactions, making it an attractive candidate for long-term management of asthma. This has been supported by several clinical trials that have demonstrated its superior efficacy compared to racemic albuterol.

The synthesis of (R)-4-Benzyl Albuterol involves complex organic transformations that require precise control over reaction conditions and stereochemistry. Advanced synthetic methodologies, such as asymmetric hydrogenation and chiral resolution techniques, are employed to ensure high enantiomeric purity. These synthetic routes not only highlight the advancements in synthetic organic chemistry but also underscore the importance of chiral drugs in modern medicine.

Recent studies have also explored the potential of (R)-4-Benzyl Albuterol as a therapeutic agent for conditions beyond respiratory disorders. For instance, its ability to modulate β2-adrenergic receptors has led researchers to investigate its potential in treating cardiovascular diseases. Preclinical data suggests that this compound may have cardioprotective effects by reducing myocardial oxygen consumption and improving coronary blood flow. These findings are particularly intriguing given the increasing prevalence of cardiovascular diseases worldwide.

The pharmacological properties of (R)-4-Benzyl Albuterol have also sparked interest in its use as a lead compound for drug discovery. By leveraging structure-activity relationship (SAR) studies, researchers have been able to modify various aspects of the molecule to enhance its therapeutic potential. For example, incorporating additional functional groups or altering the substitution pattern on the benzyl ring has led to derivatives with improved pharmacokinetic profiles and target specificity.

In conclusion, (R)-4-Benzyl Albuterol represents a significant advancement in the field of medicinal chemistry. Its unique structural features and enhanced pharmacological properties make it a promising candidate for treating various respiratory and cardiovascular conditions. As research continues to uncover new applications for this compound, it is likely that (R)-4-Benzyl Albuterol will play an increasingly important role in modern therapeutic strategies.

• 18910-70-8(O-Methyl Albuterol)
• 56796-66-8(4-Benzyl Albuterol)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)